On Wednesday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: ZS Pharma, Inc. (NASDAQ:ZSPH), Intrexon Corporation (NYSE:XON), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Array BioPharma, Inc. (NASDAQ:ARRY)

ZS Pharma, Inc. (NASDAQ:ZSPH), with shares declined -9.85%, closed at $42.

Intrexon Corporation (NYSE:XON), with shares dropped -7.73%, settled at $40.35.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), with shares dipped -8.49%, and closed at $92.86.

Array BioPharma, Inc. (NASDAQ:ARRY), plummeted -7.77%, and closed at $7.24.

Latest NEWS regarding these Stocks are depicted underneath:

ZS Pharma, Inc. (NASDAQ:ZSPH)

ZS Pharma, Inc. (ZSPH), declared the upsizing and pricing of its underwritten public offering. The size of the offering has been raised from the formerly declared 3,300,000 shares of ordinary stock to 4,015,939 shares of ordinary stock. The shares are being offered to the public at a price of $46.25 per share, resulting in aggregate proceeds to the Corporation of $185.7 million before underwriting discounts and expenses. In addition, a single selling stockholder, Alta Partners VIII, L.P., has granted the underwriters a 30-day option to purchase up to 602,390 additional shares of the Corporation’s ordinary stock at the public offering price, less underwriting discounts and commissions. The offering is predictable to close on March 30, 2015, subject to customary closing conditions.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book- running managers for the offering. BMO Capital Markets Corp. is acting as lead manager and William Blair & Corporation, L.L.C. and LifeSci Capital LLC are acting as co-managers.

The Corporation presently anticipates to use the net proceeds from the offering to complete its ongoing long-term safety trial, ZS005; complete its ongoing long-term extension study, ZS004e; fund ongoing scale-up of its active pharmaceutical ingredient, or API, manufacturing capacity; fund build-up of product inventory and launch quantities of ZS-9; and build a sales and marketing organization, counting a sales force, to support commercial sales of ZS-9 in the United States, if approved.

ZS Pharma is a publicly-traded (ZSPH), biopharmaceutical corporation with offices in Redwood City, California and Coppell, Texas. ZS Pharma’s lead therapeutic candidate, ZS-9 (sodium zirconium cyclosilicate), is an investigational treatment for hyperkalemia that is being evaluated in late-stage clinical trials to demonstrate its ability to safely and effectively remove excess potassium from the blood and maintain normal potassium levels.

Intrexon Corporation (NYSE:XON)

Soligenix, an exclusive worldwide partner of Intrexon Corporation (XON), declared recent accomplishments and financial results for the year ended December 31, 2014.

Soligenix Recent Accomplishments:

On March 11, 2015, the Corporation declared the publication of data demonstrating complete protection and immunogenicity of its heat-stable ricin vaccine, RiVax™, in preclinical studies, with analysis of previous human clinical samples. In this study, vaccination with RiVax™ offered 100% protection for non-human primates subsequently exposed to lethal doses of aerosolized ricin.

On March 3, 2015, the Corporation declared receiving a positive recommendation from the DRC to continue enrolling patients into its Phase 2 dose-ranging study evaluating SGX942, a first-in-class innate defense regulator (IDR), as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer. Following DRC review of accessible data on the subjects enrolled in the trial, the committee recommended that enrollment comprise an additional 20 subjects randomized into either a single SGX942 dose group or the placebo group to allow for a more targeted assessment of the drug’s potential effect and to inform final dose selection in this patient population.

On February 11, 2015, the Corporation declared that it presented preclinical melioidosis results at the 2015 ASM BioDefense and Emerging Disease Research meeting held in Washington, DC. The data from the preclinical study demonstrated statistically noteworthy efficacy of SGX943 in a mouse model of acute, lethal pneumonic melioidosis.

On January 29, 2015, the Corporation declared the publication of data demonstrating improved immunogenicity and rapid action of its heat-stable anthrax vaccine, VeloThrax™. The use of the Corporation’s proprietary vaccine stabilization technology, ThermoVax™, has been formerly demonstrated to enhance the thermostability of VeloThrax™, enabling distribution without cold chain requirements.

On January 7, 2015, the Corporation declared that the SGX301 (synthetic hypericin) development program for first-line treatment of CTCL received “Fast Track” designation from the US Food and Drug Administration.

On January 5, 2015, the Corporation declared preliminary efficacy had been demonstrated in an animal model of Macrophage Activation Syndrome (MAS) with its SGX94 IDR technology, significantly mitigating the pancytopenia characteristic of MAS.

On December 24, 2014, the Corporation declared the closing of a registered public offering of 1,886,530 units at an offering price of $1.21 per unit, with each unit comprising of one share of ordinary stock and 0.6 of a warrant to purchase one share of ordinary stock with an exercise price of $1.48. The Corporation raised about $2.3 million in gross proceeds to fund its research and development activities counting the conduct of a pivotal Phase 3 clinical trial of SGX301 for the treatment of CTCL.

On December 11, 2014, the Corporation declared receiving about $617,000, net of transaction costs, via the State of New Jersey’s Technology Business Tax Certificate Transfer Program.

On December 10, 2014, the Corporation declared the appointment of Oreola Donini, PhD, as Senior Vice President and Chief Scientific Officer.

On November 17, 2014, the Corporation declared the formation of a Medical Advisory Board to provide medical/clinical planned guidance as the Corporation advances the Phase 3 clinical development of SGX301 for the treatment of CTCL.

Intrexon Corporation, a biotechnology corporation, operates in the synthetic biology field in the United States. The corporation, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that comprise of key genetic components.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. (AGIO), declared that the United States Food and Drug Administration (FDA) has granted the corporation orphan drug designation for its investigational medicine AG-348 for the treatment of pyruvate kinase (PK) deficiency, a rare form of hemolytic anemia. AG-348, a first-in-class, orally accessible activator of pyruvate kinase-R (PKR) enzymes, met its primary endpoints in two Phase 1 healthy volunteer studies — a single ascending dose study and multiple ascending dose study. In addition, data presented in December 2014 at the 54th Annual Meeting of the American Society of Hematology (ASH) offered early proof-of-mechanism for AG-348. Based on these findings, Agios plans to initiate a Phase 2 clinical trial in patients with PK deficiency in the first half of 2015.

The FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for underserved patient populations, or rare disorders that affect fewer than 200,000 people in the U.S. This designation provides certain benefits, counting market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States.

Array BioPharma, Inc. (NASDAQ:ARRY)

Formerly on March 2, Array BioPharma, Inc. (ARRY), declared the completion of both the binimetinib and encorafenib definitive contracts with Novartis. Together with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.

Leadership Changes:

Array declared that Andrew Robbins, Array’s Senior Vice President of Commercial Operations, has been designated Chief Operating Officer, with responsibility for sales, marketing, manufacturing and business development activities at Array. In this expanded role, Mr. Robbins will be instrumental in ensuring successful commercialization of binimetinib and encorafenib.

Ron Squarer noted, “Since joining Array, Mr. Robbins has established himself as a key member of the leadership team, assisting to shape Array’s strategy and execute our plans. I am confident in his ability to lead in this broader role as we evolve into a fully-integrated biopharmaceutical corporation.”

Array also declared that Dr. David Snitman, Chief Operating Officer, has declared his intention to retire at the end of June 2015. Until that time, Dr. Snitman will serve as Executive Vice President of Business Development.

“Since co-founding Array 17 years ago, Dr. Snitman has been instrumental in creating planned partnerships that have been key to the growth and success of the corporation,” said Mr. Squarer. “The Array Board of Directors and I wish to thank him for his dedication and service.”

Array BioPharma Inc., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.